The roles of CD73 in cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Gao, Zhao Wei ^a   Dong, Ke ^a   Zhang, Hui Zhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ALPHA INTERFERON; BETA INTERFERON; BEVACIZUMAB; CASPASE 3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PROTEIN BAX; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ADENOSINE; ADENOSINE PHOSPHATE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; BLADDER CANCER CELL LINE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GALLBLADDER CANCER; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE METASTASIS; MEDULLOBLASTOMA; MELANOMA; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE MONOPHOSPHATE; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84929057232     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/460654     Document Type: Review

References (74)

1. G. Burnstock and F. Di Virgilio, "Purinergic signalling and cancer, " Purinergic Signalling, vol. 9, no. 4, pp. 491-324, 2013.
2. M. Helenius, S. Jalkanen, and G. G. Yegutkin, "Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids, " Biochimica et Biophysica Acta: Molecular Cell Research, vol. 1823, no. 10, pp. 1967-1975, 2012.
3. M. J. L. Bours, E. L. R. Swennen, F. di Virgilio, B. N. Cronstein, and P. C. Dagnelie, "Adenosine 5′-triphosphate and adenosine as endogenous signalingmolecules in immunity and inflammation, " Pharmacology and Therapeutics, vol. 112, no. 2, pp. 358-404, 2006.
4. G. G. Yegutkin, "Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade, " Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 673-694, 2008.
5. J. Stagg and M. J. Smyth, "Extracellular adenosine triphosphate and adenosine in cancer, " Oncogene, vol. 29, no. 39, pp. 5346-5358, 2010.
6. F. Ghiringhelli, M. Bruchard, F. Chalmin, and C. Rebe, "Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape, " Journal of Biomedicine and Biotechnology, vol. 2012, Article ID473712, 9 pages, 2012.
7. X. Zhi, S. Chen, P. Zhou et al., "RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion, " Clinical and ExperimentalMetastasis, vol. 24, no. 6, pp. 439-448, 2007.
8. C. Quezada, W. Garrido, C. Oyarzun et al., "5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells, " Journal of Cellular Physiology, vol. 228, no. 3, pp. 602-608, 2013.
9. H. Wang, S. Lee, C. Lo Nigro et al., "NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity, " British Journal of Cancer, vol. 106, no. 8, pp. 1446-1452, 2012.
10. R. Sadej and A. C. Skladanowski, "Dual, enzymatic and nonenzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375melanoma cells, " Acta Biochimica Polonica, vol. 59, no. 4, pp. 647-652, 2012.
11. J. Stagg, U. Divisekera, N. McLaughlin et al., "Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1547-1552, 2010.
12. D. Jin, J. Fan, L. Wang et al., "CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumorinduced immune suppression, " Cancer Research, vol. 70, no. 6, pp. 2245-2255, 2010.
13. L. Wang, X. Zhou, T. Zhou et al., "Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells, " Journal of Cancer Research and Clinical Oncology, vol. 134, no. 3, pp. 365-372, 2008.
14. A. R. Cappellari, L. Rockenbach, F. Dietrich et al., "Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5′NT/CD73 in metastasis as potential prognostic factor, " PLoS ONE, vol. 7, no. 10, Article IDe47468, 2012.
15. J. Stella, L. Bavaresco, E. Braganhol et al., "Differential ectonucleotidase expression in human bladder cancer cell lines, " Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 3, pp. 260-267, 2010.
16. N. Liu, X. D. Fang, and Q. Vadis, "CD73 as a novel prognostic biomarker for human colorectal cancer, " Journal of Surgical Oncology, vol. 106, no. 7, pp. 918-919, 2012.
17. X. Wu, X. He, Y. Chen et al., "High expression of CD73 as a poor prognostic biomarker in human colorectal cancer, " Journal of Surgical Oncology, vol. 106, no. 2, pp. 130-137, 2012.
18. H. K. Oh, J. I. Sin, J. Choi, S. H. Park, T. S. Lee, and Y. S. Choi, "Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory t cell infiltration, " Journal of Gynecologic Oncology, vol. 23, no. 4, pp. 274-281, 2012.
19. X. X. Lu, Y. T. Chen, B. Feng, X. Y. Mao, B. Yu, and X. Chu, "Expression and clinical significance of CD73 and hypoxiainducible factor-1α in gastric carcinoma, " World Journal of Gastroenterology, vol. 19, no. 12, pp. 1912-1918, 2013.
20. L. Xiong, Y. Wen, X. Miao, and Z. Yang, "NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer, " Cell and Tissue Research, vol. 355, no. 2, pp. 365-374, 2014.
21. S. X. Zhao, H. M. Zhang, S. X. Dong et al., "Characteristics and clinical significance of CD73 expression in subtypes of leukemia, " Journal of experimental hematology/Chinese Association of Pathophysiology, vol. 19, no. 5, pp. 1141-1144, 2011.
22. S. Serra, A. L. Horenstein, T. Vaisitti et al., "CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death, " Blood, vol. 118, no. 23, pp. 6141-6152, 2011.
23. E. Wieten, B. E. M. van der Linden-Schrever, E. Sonneveld, A. J. Veerman, and R. Pieters, "CD73 (5′-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia, " Leukemia, vol. 25, no. 8, pp. 1374-1376, 2011.
24. Q. Yang, J. Du, and L. Zu, "Overexpression of CD73 in prostate cancer is associated with lymph node metastasis, " Pathology Oncology Research, vol. 19, no. 4, pp. 811-814, 2013.
25. A. Supernat, M. Wenicka-Jaskiewicz, A. Markiewicz et al., "CD73 expression as a potential marker of good prognosis in breast carcinoma, " Applied Immunohistochemistry and Molecular Morphology, vol. 20, no. 2, pp. 103-107, 2012.
26. S. Loi, S. Pommey, B. Haibe-Kains et al., "CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 27, pp. 11091-11096, 2013.
27. B. Zhang, "CD73 promotes tumor growth and metastasis, " Oncoimmunology, vol. 1, no. 1, pp. 67-70, 2012.
28. B. Zhang, "Opportunities and challenges for anti-CD73 cancer therapy, " Immunotherapy, vol. 4, no. 9, pp. 861-865, 2012.
29. J. Stagg, "The double-edge sword effect of anti-CD73 cancer therapy, " Oncoimmunology, vol. 1, no. 2, pp. 217-218, 2012.
30. P. Ujhazy, E. S. Berleth, J. M. Pietkiewicz et al., "Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance, " International Journal of Cancer, vol. 68, no. 4, pp. 493-500, 1996.
31. W. Garrido, M. Munoz, R. SanMartin, and C. Quezada, "FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1, " Biochemical and Biophysical Research Communications, vol. 411, no. 1, pp. 62-68, 2011.
32. X. Zhi, Y. Wang, X. Zhou et al., "RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells, " Cancer Science, vol. 101, no. 12, pp. 2561-2569, 2010.
33. X. Zhou, X. Zhi, P. Zhou et al., "Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo, " Oncology Reports, vol. 17, no. 6, pp. 1341-1346, 2007.
34. L. Rockenbach, L. Bavaresco, P. Fernandes Farias et al., "Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells, " Urologic Oncology, vol. 31, no. 7, pp. 1204-1211, 2013.
35. L. Bavaresco, A. Bernardi, E. Braganhol et al., "The role of ecto-5′nucleotidase/CD73 in glioma cell line proliferation, " Molecular and Cellular Biochemistry, vol. 319, no. 1-2, pp. 61-68, 2008.
36. M. Wang and L. Ren, "Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine, " Acta Pharmacologica Sinica, vol. 27, no. 8, pp. 1085-1092, 2006.
37. S. Shirali, M. Aghaei, M. Shabani, M. Fathi, M. Sohrabi, and M. Moeinifard, "Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3, " Tumor Biology, vol. 34, no. 2, pp. 1085-1095, 2013.
38. X. Zhi, Y. Wang, J. Yu et al., "Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer, " IUBMB Life, vol. 64, no. 11, pp. 911-920, 2012.
39. J. Stagg, P. A. Beavis, U. Divisekera et al., "CD73-Deficient mice are resistant to carcinogenesis, " Cancer Research, vol. 72, no. 9, pp. 2190-2196, 2012.
40. G. G. Yegutkin, F. Marttila-Ichihara, M. Karikoski et al., "Altered purinergic signaling in CD73-deficient mice inhibits tumor progression, " European Journal of Immunology, vol. 41, no. 5, pp. 1231-1241, 2011.
41. P. Zhou, X. Zhi, T. Zhou et al., "Overexpression of ecto-5′-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix, " Cancer Biology andTherapy, vol. 6, no. 3, pp. 426-431, 2007.
42. J. Stagg, U. Divisekera, H. Duret et al., "CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis, " Cancer Research, vol. 71, no. 8, pp. 2892-2900, 2011.
43. L. Wang, S. Tang, Y. Wang et al., "Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis, " Clinical and Experimental Metastasis, vol. 30, no. 5, pp. 671-680, 2013.
44. P. Koszalka, A. Pryszlak, M. Golunska et al., "Inhibition ofCD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo, " Oncology Reports, vol. 31, no. 2, pp. 819-827, 2014.
45. B. Allard, M. Turcotte, K. Spring, S. Pommey, I. Royal, and J. Stagg, "Anti-CD73 therapy impairs tumor angiogenesis, " International Journal of Cancer, vol. 134, no. 6, pp. 1466-1473, 2014.
46. Y. C. Boring, U. Flogel, C. Jacoby, M. Heil, W. Schaper, and J. Schrader, "Lack of ecto-5′-nucleotidase (CD73) promotes arteriogenesis, " Cardiovascular Research, vol. 97, no. 1, pp. 88-96, 2013.
47. S. Giuliano and G. Pages, "Mechanisms of resistance to antiangiogenesis therapies, " Biochimie, vol. 95, no. 6, pp. 1110-1119, 2013.
48. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
49. L. Antonioli, P. Pacher, E. S. Vizi, and G. Hasko, "CD39 and CD73 in immunity and inflammation, " Trends in Molecular Medicine, vol. 19, no. 6, pp. 355-367, 2013.
50. M. S. Longhi, S. C. Robson, S. H. Bernstein, S. Serra, and S. Deaglio, "Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states, " Journal of Molecular Medicine, vol. 91, no. 2, pp. 165-172, 2013.
51. P. A. Beavis, J. Stagg, P. K. Darcy, and M. J. Smyth, "CD73: a potent suppressor of antitumor immune responses, " Trends in Immunology, vol. 33, no. 5, pp. 231-237, 2012.
52. V. Kumar, "Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?" Purinergic Signalling, vol. 9, no. 2, pp. 145-165, 2013.
53. R. Sorrentino, A. Pinto, and S. Morello, "The adenosinergic system in cancer: key therapeutic target, " Oncoimmunology, vol. 2, no. 1, Article IDe22448, 2013.
54. T. Raskovalova, X. Huang, M. Sitkovsky, L. C. Zacharia, E. K. Jackson, and E. Gorelik, "GS protein-coupled adenosine receptor signaling and lytic function of activated NK cells, " Journal of Immunology, vol. 175, no. 7, pp. 4383-4391, 2005.
55. S. V. Novitskiy, S. Ryzhov, R. Zaynagetdinov et al., "Adenosine receptors in regulation of dendritic cell differentiation and function, " Blood, vol. 112, no. 5, pp. 1822-1831, 2008.
56. T. L. Whiteside, M. Mandapathil, and P. Schuler, "The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg), " CurrentMedicinal Chemistry, vol. 18, no. 34, pp. 5217-5223, 2011.
57. S. Ryzhov, S. V. Novitskiy, A. E. Goldstein et al., "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells, " Journal of Immunology, vol. 187, no. 11, pp. 6120-6129, 2011.
58. M. R. Wink, A. S. K. Tamajusuku, E. Braganhol et al., "Thyroid hormone upregulates ecto-5′-nucleotidase/CD73 in C6 rat glioma cells, "Molecular and Cellular Endocrinology, vol. 205, no. 1-2, pp. 107-114, 2003.
59. A. S. K. Tamajusuku, M. A. Carrillo-Sepulveda, E. Braganhol et al., "Activity and expression of ecto-5′-nucleotidase/CD73 are increased by thyroid hormones in vascular smooth muscle cells, " Molecular and Cellular Biochemistry, vol. 289, no. 1-2, pp. 65-72, 2006.
60. M. S. Carneiro-Ramos, V. B. da Silva, M. B. Coutinho Jr., A. M. Oliveira Battastini, J. J. Freitas Sarkis, and M. L. M. Barreto-Chaves, "Thyroid hormone stimulates 5′-ecto-nucleotidase of neonatal rat ventricular myocytes, " Molecular and Cellular Biochemistry, vol. 265, no. 1-2, pp. 195-201, 2004.
61. G. L. Semenza, "Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning, " Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1813, no. 7, pp. 1263-1268, 2011.
62. X. Li, T. Zhou, X. Zhi, F. Zhao, L. Yin, and P. Zhou, "Effect of hypoxia/reoxygenation on CD73 (ecto-5′-nucleotidase) in mouse microvessel endothelial cell lines, " Microvascular Research, vol. 72, no. 1-2, pp. 48-53, 2006.
63. D. Brisevac, I. Bjelobaba, A. Bajic et al., "Regulation of ecto-5′-nucleotidase (CD73) in cultured cortical astrocytes by different inflammatory factors, " Neurochemistry International, vol. 61, no. 5, pp. 681-688, 2012.
64. J. Niemela, T. Henttinen, G. G. Yegutkin et al., "IFN-α induced adenosine production on the endothelium: amechanism mediated by CD73 (Ecto-5′-Nucleotidase) up-regulation, " Journal of Immunology, vol. 172, no. 3, pp. 1646-1653, 2004.
65. L. Airas, J. Niemela, G. Yegutkin, and S. Jalkanen, "Mechanism of action of IFN-β in the treatment of multiple sclerosis: a special reference to CD73 and adenosine, " Annals of the New York Academy of Sciences, vol. 1110, pp. 641-648, 2007.
66. J. Kiss, G. G. Yegutkin, K. Koskinen, T. Savunen, S. Jalkanen, and M. Salmi, "IFN-β protects from vascular leakage via upregulation of CD73, " European Journal of Immunology, vol. 37, no. 12, pp. 3334-3338, 2007.
67. C. Lo Nigro, M. Monteverde, S. Lee et al., "NT5E CpG island methylation is a favourable breast cancer biomarker, " British Journal of Cancer, vol. 107, no. 1, pp. 75-83, 2012.
68. J. Spychala and J. Kitajewski, "Wnt and β-catenin signaling target the expression of ecto-5′-nucleotidase and increase extracellular adenosine generation, " Experimental Cell Research, vol. 296, no. 2, pp. 99-108, 2004.
69. V. T. Thom, M. Wendel, and A. Deussen, "Regulation of ecto-5′-nucleotidase by docosahexaenoic acid in human endothelial cells, " Cellular Physiology and Biochemistry, vol. 32, no. 2, pp. 355-366, 2013.
70. S. Narravula, P. F. Lennon, B. U. Mueller, and S. P. Colgan, "Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function, " Journal of Immunology, vol. 165, no. 9, pp. 5262-5268, 2000.
71. S. F. Hausler, I. M. del Barrio, J. Diessner et al., "Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion, " American Journal of Translational Research, vol. 6, no. 2, pp. 129-139, 2014.
72. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy, " Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
73. B. Allard, S. Pommey, M. J. Smyth, and J. Stagg, "TargetingCD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs, " Clinical Cancer Research, vol. 19, no. 20, pp. 5626-5635, 2013.
74. R. Iannone, L. Miele, P. Maiolino, A. Pinto, and S. Morello, "Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mousemelanomamodel, " American Journal of Cancer Research, vol. 4, no. 2, pp. 172-181, 2014.